Latest Articles
Baylen Dupree tears up discussing possible infertility due to endometriosis: ‘Everything is unknown’ (exclusive) - MSN
Baylen Dupree tears up discussing possible infertility due to endometriosis: ‘Everything is unknown’ (exclusive) MSN
Published: June 24, 2026, 2:24 p.m.
Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions - insider.fitt.co
Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions insider.fitt.co
Published: June 24, 2026, 2:13 p.m.
Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions - Fitt Insider
Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions Fitt Insider
Published: June 24, 2026, 2:13 p.m.
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Benzinga
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program Benzinga
Published: June 24, 2026, 1:09 p.m.
WHO Guidelines: What You Must Know About the Endometriosis Crisis - streamlinefeed.co.ke
WHO Guidelines: What You Must Know About the Endometriosis Crisis streamlinefeed.co.ke
Published: June 24, 2026, 11:46 a.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com
Published: June 24, 2026, 11:25 a.m.
Absci stock surges 24% on positive Phase 1 hair loss drug data - Investing.com South Africa
Absci stock surges 24% on positive Phase 1 hair loss drug data Investing.com South Africa
Published: June 24, 2026, 11:14 a.m.
Absci stock surges 24% on positive Phase 1 hair loss drug data By Investing.com - Investing.com India
Absci stock surges 24% on positive Phase 1 hair loss drug data By Investing.com Investing.com India
Published: June 24, 2026, 11:13 a.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times
Published: June 24, 2026, 10:48 a.m.
Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart - Minichart
Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart Minichart
Published: June 24, 2026, 10:45 a.m.
Link copied to clipboard!